Biotech Values

[mouton29]

The text of the order, I used the Acrobat OCR software to convert the image to text.


BARBARA S. JONES
UNITED STATES DISTRICT JUDGE
09 C
(
. 8824
(AJP)
Order
On April 4/ 2011/ Plaintiffs Teva Pharmaceuticals USAf
Inc., Teva Pharmaceutical Industries, Ltd., Teva Neuroscience,
Inc., and Yeda Research and Development Co./ Inc. moved against
Defendants Sandoz, Inc., Sandoz International GmbH, Novartis AG,
Momenta Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Mylan
Inc., and Natco Pharma Ltd. for a summary judgment finding of no
inequitable conduct. (Dkt.218.)

Upon review of all of the part s/ legal papers and postbriefing
letters regarding the implications of the Federal
Circuit/s en bane decision in . Becton
Dickinson and Company, Nos. 2008-1511/ 2011 WL 2028255 (Fed.
Case 1:09-cv-08824-BSJ Document 141 Filed 06/17/11 Page 2 of 2
Cir. May 25, 2011), the Court finds there are disputed issues of
material fact regarding Defendants' affirmative defense of
inequitable conduct. Accordingly, plaintiffs' motion for a
summary judgment finding of no inequitable conduct (Dkt. 218) lS
DENIED.

A bench trial regarding Defendants' inequitable conduct
affirmative de se will commence on July 11, 2011 at 9:30 a.m.
in Courtroom 17C of the United States District Court, 500 Pearl
Street, New York, NY 10007.
SO ORDERED: